1 minute read
Dec. 16, 2021

Ceralasertib: a Serine/Threonine Kinase Inhibitor

ceralasertib (AZD6738)

ATR serine/threonine kinase inhibitor oral agent in Ph. II for cancer from mTOR-program derived hit + opt. Clinical Cancer Research AstraZeneca, Cambridge, UK

twitterlinkedinprintemail